40 million people in the US qualify for hearing loss treatment, but there are no drugs approved for hearing loss. Drug delivery to the inner ear remains the hardest challenge.
Precise, non-invasive placement techniques, combined with long-acting delivery systems have the potential to overcome the barriers of drug delivery to the inner ear.
Inflammation and neurodegeneration are the origin of 90% of inner ear disorders. Biomarkers of active disease and improved patient selection are necessary to overcome the challenges of clinical development.
Inspired by ophthalmology, Spiral's platform addresses hearing loss by delivering the right drugs, to the right place, for the right duration.